KE

ANALYST NOTE: KIMBALL ELECTRONICS, INC. (KE) DATE: 2026-06-13

1. Structural Readiness

Current Price: $25.30 Extension: — (Price is within the base structure, not in an extension phase) Conservative Entry: — (Not yet actionable; requires confirmed breakout) Aggressive Entry: $24.95 (Pre-breakout / forming entry) Breakout Level: $33.19 (Resistance level that must be cleared to confirm the setup)

Classification: The setup is FORMING.

• Volatility Context: Current ATR is 4.8% (High). This sits within the historical "sweet spot" (4–6%) for structural quality, suggesting sufficient volatility to support a move without the extreme risk associated with >8% ATR.

2. Thesis Layer

Thesis Status: TACTICAL / SETUP-LED There is no named secular thesis attached to this setup as of 2026-06-13. This is not a macro-driven play (e.g., "AI Infrastructure Boom" or "Green Energy Transition"). The investment case is strictly derived from the quality of the technical structure (the forming coil) combined with the company's specific operational fundamentals.

• Judgment Criteria: Conviction must be weighed entirely on the setup quality (the 69% historical probability of a breakout from this specific formation) and the strength of the business fundamentals provided in the evidence. Do not invent a macro narrative to justify the trade.

3. Business Overview

Company: Kimball Electronics, Inc. (KE) Industry: Contract Electronics Manufacturing (CEM) / Contract Manufacturing Organization (CMO) Business Model: KE provides comprehensive CEM and diversified production solutions, including engineering, supply chain management, and rapid prototyping. The company serves clients across the Automotive, Medical, Industrial, and Public Safety sectors.

Key Operational Highlights (as of 2026-06-13):

• Geographic Footprint: The company operates globally with facilities in the United States, China, Mexico, Poland, Romania, Thailand, and Vietnam (Evidence [E14]).
• Core Competencies: Specializes in precision-injected molded plastics, complete device assembly, cold chain management, and the production of medical disposables, surgical instruments, and drug delivery devices (Evidence [E6], [E9]).
• Recent Expansion: As of August 2025, KE executed a lease for a third manufacturing facility in Indiana to expand its medical CMO footprint (Evidence [E11]).
• Growth Strategy: Management targets adding 5 new customers annually (Evidence [E8]). The path to revenue realization for new CMO programs is estimated at 18 to 36 months (Evidence [E7]).

Financial Guidance & Performance (Source: Q4 FY2026 Earnings Call, 2026-05-06):

• Revenue Guidance: Affirmed range of $1.4 billion to $1.46 billion for the fiscal year (Evidence [E2]).
• Margin Guidance: Affirmed adjusted operating margin guidance of 4.2% to 4.5%, with management expecting the result to land at the high end of this range (Evidence [E1], [E2]).
• Margin Headwinds: Management explicitly warned that gross margin will face pressure in Fiscal 2027 due to the ramp-up of the new Indiana facility. They expect a 40 to 50 basis point impact to gross margin in FY '27 related to these facility costs (Evidence [E3], [E4]).
• Growth Drivers: Q3 growth (adjusted for prior year inventory sales) was driven by increases in Asia and North America, specifically in respiratory care, imaging systems, drug delivery devices, and blood separation products (Evidence [E5]).

4. Archetype and Conviction Stack

Archetype: Growth Leader This classification fits the company's trajectory of expanding capacity (Indiana facility), targeting new customer acquisition (5/year), and delivering revenue growth in high-barrier sectors (medical/automotive).

Conviction Stack Analysis:

• Thesis Strength: Low (Tactical only; no secular tailwind).
• Evidence Quality: High. The evidence base is robust, containing specific earnings guidance, facility expansion details, and clear margin expectations.
• Setup Readiness: Partial. The 69% historical breakout rate for this specific formation is a strong statistical edge, but the setup is not yet "confirmed."
• Rerating Potential: Moderate. The market is currently pricing in the margin pressure from the new facility (40-50 bps impact). If the company delivers on the "high end" of the margin guidance for FY2026 while the new facility ramps, the stock could re-rate as the cost headwinds abate (as management expects).

Valuation Context: Forward consensus EPS is $1.4575 for FY1 and $1.30 for FY2 (Evidence [E20]). The current price of $25.30 implies a forward P/E of approximately 17.4x for FY1. This valuation must be weighed against the 4.2-4.5% operating margin guidance.

5. Invalidations, Strengths, and Gaps

What Would Invalidate the Case:

• Fundamental: A miss on the FY2026 revenue guidance ($1.4B-$1.46B) or a failure to achieve the high-end of the margin guidance (4.5%), particularly if the new facility ramp causes margin compression beyond the expected 40-50 bps.

What Would Strengthen the Case:

• Technical: A daily close above $33.19 (Breakout level). This would confirm the coil and trigger the "confirmed" state.
• Fundamental: Confirmation that the new Indiana facility is ramping faster than the 18-36 month timeline, or that the "high end" of the margin guidance is achieved despite the facility costs.

Gaps in Evidence:

• Missing Evidence: There is no specific data on the *current* backlog size or the specific revenue contribution of the new Indiana facility as of June 2026.
• Missing Evidence: No specific data on the *current* gross margin percentage for Q1/Q2 FY2026 to compare against the FY2027 forecast.
• Missing Evidence: No specific data on the *current* customer count to verify the "5 new customers annually" target progress.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key risks: Technical invalidation if price closes below $24.13; Gross margin compression of 40-50 bps in FY2027 due to new facility ramp-up; Lack of a named secular thesis to provide macro tailwinds; 18-36 month lag time for new CMO programs to generate revenue. Sizing hint: Position size should reflect the "forming" (partial) nature of the setup; smaller than a confirmed breakout position. Expected path: Price consolidates near current levels while management executes the facility ramp; potential breakout above $33.19 if earnings momentum holds and facility costs stabilize. Expected horizon: 3 to 6 months for the breakout or invalidation to resolve. Failure mode to watch: A daily close below $24.13, which would signal the coil structure has failed and the setup is invalidated.